Deals Of The Week: Amgen/Micromet, Celgene/Avila, Watson/Ascent
Executive Summary
Along with three biotech acquisitions, the week in deal-making also saw the licensing of a new hepatitis C candidate with a different mechanism of action, further consolidation in the animal health field, and the end of Ipsen and Santhera’s collaboration on Alzheimer’s drug fipamezole.